Related Experiment Videos
Allogeneic transplantation across the HLA barriers
F Aversa1, A Tabilio, A Velardi
1Hematopoietic Stem Cell Transplant Program, Section of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy. aversa@unipg.it
Reviews in Clinical and Experimental Hematology
|August 7, 2001
Summary
Megadose stem cell transplants using T-cell-depleted, one-haplotype-mismatched grafts achieve sustained engraftment without graft-vs.-host disease in high-risk acute leukemia patients. This approach makes haploidentical transplantation a viable option for nearly all transplant candidates.
Area of Science:
- Hematology
- Immunology
- Transplantation Medicine
Background:
- High-risk acute leukemia patients often lack suitable matched donors for hematopoietic stem cell transplantation.
- Conventional allogeneic transplantation is limited by donor availability and graft-versus-host disease (GVHD).
Purpose of the Study:
- To establish the efficacy and safety of megadose, T-cell-depleted, one-haplotype-mismatched stem cell transplantation.
- To overcome donor limitations and GVHD in acute leukemia patients requiring stem cell transplants.
Main Methods:
- Utilized a megadose of extensively T-cell-depleted hematopoietic stem cells.
- Developed novel conditioning regimens and optimized graft processing.
- Focused on improving post-transplant immunologic recovery.
Main Results:
- Achieved sustained full-donor engraftment in over 100 high-risk acute leukemia patients.
- Demonstrated the absence of graft-versus-host disease.
- Established haploidentical transplantation as a clinical reality.
Conclusions:
- Megadose, T-cell-depleted, one-haplotype-mismatched stem cell transplantation is effective for high-risk acute leukemia.
- This strategy significantly expands the pool of eligible candidates for curative allogeneic transplantation.
- Haploidentical transplantation offers a viable alternative for patients with mismatched family donors.